450 patients join study to personalize neuroendocrine tumor care

NCT ID NCT06356467

Recruiting now Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jan 18, 2026 · Last updated May 03, 2026 · Updated 13 times

Summary

This study looks at how things like age, sex, tumor grade, and location affect how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NENs). Researchers will track 450 adults who have received standard therapies like somatostatin analogs or chemotherapy. The goal is to better predict which treatments work best for each patient, helping doctors personalize care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

IRCCS OSpedale San Raffaele
RECRUITING

Milan, 20132, Italy

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

GEP-NET NEUROENDOCRINE TUMORS